Are U.S. And Russian Opioid Abusers Comparable?
You may also be interested in...
US FDA’s Foreign Data Policy Faces Its Greatest Test From Chinese PD-1/L1 Inhibitors
The swift rise of China’s oncology R&D has put at least four novel applications before FDA with pivotal data generated only in China.
In Multinational Trials, U.S. Often Lags In Efficacy, FDA Analysis Finds
As drug developers continue to move clinical trials overseas, FDA is keeping a close eye on the differential results that sometimes arise between U.S. and foreign subject populations, potentially affecting the usability of hard-won data for drug applications.
In Multinational Trials, U.S. Often Lags In Efficacy, FDA Analysis Finds
As drug developers continue to move clinical trials overseas, FDA is keeping a close eye on the differential results that sometimes arise between U.S. and foreign subject populations, potentially affecting the usability of hard-won data for drug applications.